BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

Spero Therapeutics (SPRO)Spero TherapeuticsEarnings

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025

Existing cash, together with earned development...

Related news

SPROSpero Therapeutics2026-05-13 21:05 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

COCPCocrystal Pharma2026-05-15 12:00 EST

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ASMBAssembly Biosciences2026-05-07 20:00 EST

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Stock data

Close
1.22 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States